ACTOS (PIOGLITAZONE): NEW THERAPY FOR TYPE 2 DIABETES WITH NOVEL MODE OF ACTION LAUNCHED IN UKNovember 07, 2000“Type 2 diabetes is characterised by high blood sugar but also by lipid abnormalities, particularly raised triglycerides and low HDL (so-called good) cholesterol. This spectrum of metabolic imbalance related to insulin resistance together with raised blood pressure is the characteristic signature of most people with Type 2 diabetes. Any compound with the ability to improve this metabolic spectrum has great potential to improve the treatment of Type 2 diabetes” according to Professor John Betteridge, Professor of Endocrinology and Metabolism at University College, London. Professor Betteridge added “Pioglitazone, from available scientific evidence, reduces insulin resistance helping to address these metabolic concerns”. Takeda UK Limited today announced that ACTOS® (pioglitazone) is now available in the UK for the treatment of Type 2 diabetes mellitus. ACTOS is approved for use in the oral combination treatment of Type 2 diabetes mellitus in patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin (in obese patients) or a sulphonylurea (in patients for whom metformin is not tolerated or contraindicated). ACTOS® is taken once daily and is available in 15 and 30 milligram tablets. Dr David Kerr, Consultant Physician, Bournemouth Diabetes & Endocrinology Centre, The Royal Bournemouth Hospital said “The availability of pioglitazone is good news for both patients and doctors. By improving insulin sensitivity, pioglitazone in combination with metformin and a sulphonylurea significantly reduces blood glucose levels which is vital when trying to manage Type 2 diabetes. In addition, pioglitazone in combination therapy decreased triglycerides and increased high density lipoprotein cholesterol (HDL-C) with no significant effect on low density lipoprotein cholesterol (LDL-C) compared to placebo.” It is estimated that 1.4 million people in the UK have diabetes.1 Of these, between 75% and 90% have Type 2 diabetes.1 Dr Roger Gadsby a General Practitioner in Warwick commented that “The treatment of Type 2 diabetes is largely a condition managed in primary care. Any therapy, such as pioglitazone, that is taken once a day and is easy to use will be a valuable addition to the physician’s armamentarium. I believe that pioglitazone has these characteristics.” For further information, please contact: Tara Mistry (Tel: 020 7345 3419) or Helen Robinson (Tel: 020 7345 3414) at Ogilvy Public Relations Worldwide. Note to Editors: Type 2 diabetes Type 2 diabetes is a chronic illness characterised by an abnormally high level of glucose (sugar) in the blood. As Type 2 diabetes progresses, the heart, the circulation, the eyes and the kidneys can all be affected and severe complications can arise which may cause severe disability and restrict a patient’s mobility and ability to work. The cost of treating Type 2 diabetes and its associated complications is projected to total £4.8 billion in 2000. This accounts for approximately 9% of total NHS resources.1 ACTOS® ACTOS® is a member of the thiazolidinedione class of drugs commonly known as insulin sensitizers or glitazones. ACTOS® helps restore the body’s ability to effectively use its own insulin by reducing insulin resistance, which has been identified as a primary defect in Type 2 diabetes. By improving sensitivity to insulin, ACTOS® in combination with other antidiabetic therapies significantly reduced raised blood glucose levels. Takeda Takeda is the largest pharmaceutical company in Japan and is one of the world’s top 20 pharmaceutical companies. Takeda is committed to the research and development of novel drug therapies. Takeda has been investing in research into diabetes for over 30 years and were the originators of the thiazolidinedione class of drugs and the company is constantly striving to contribute to the treatment of Type 2 diabetes. Takeda UK Ltd. is a wholly owned subsidiary of Takeda Chemical Industries, Ltd. References 1. Diabetes UK. Diabetes Fact Sheet. June 2000. Date of Preparation: October 2000 AC001027b Ogilvy Public Relations Worldwide |
|||||||||||||||||||||
| Related Diabetes Current Events and Diabetes News Articles Flaxseed oil and osteoporosis Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health. Diabetes surgery summit consensus lays foundation for new field of medicine A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. ESC to give talks on Diabetes in three cities in China As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou. New research shows versatility of amniotic fluid stem cells For the first time, scientists have demonstrated that stem cells found in amniotic fluid meet an important test of potential to become specialized cell types, which suggests they may be useful for treating a wider array of diseases and conditions than scientists originally thought. First reconstitution of an epidermis from human embryonic stem cells Stem cell research is making great strides. This is yet again illustrated by a study carried out by the I-STEM* Institute (I-STEM/ Inserm UEVE U861/AFM), published in the Lancet on 21 November 2009. The I-STEM team, directed by Marc Peschanski has just succeeded in recreating a whole epidermis from human embryonic stem cells. An atomic-level look at an HIV accomplice Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity. Scripps research scientists find new link between insulin and core body temperature A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature. Scientists find molecular trigger that helps prevent aging and disease Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease? Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Night Beat, Overtime and a Disrupted Sleep Pattern Can Harm Officers' Health A police officer who works the night shift, typically from 8 p.m. to 4 a.m., already is at a disadvantage when it comes to getting a good "night's" sleep. More Diabetes Current Events and Diabetes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||